M
Michelle T. Marra
Researcher at Pfizer
Publications - 4
Citations - 456
Michelle T. Marra is an academic researcher from Pfizer. The author has contributed to research in topics: Coronavirus & Drug delivery. The author has an hindex of 4, co-authored 4 publications receiving 139 citations.
Papers
More filters
Journal ArticleDOI
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Robert Louis Hoffman,Robert Steven Kania,Jay F. Davies,Rose Ann Ferre,Ketan S. Gajiwala,Mingying He,Robert J. Hogan,Kirk Kozminski,Lilian Y. Li,Jonathan W. Lockner,Jihong Lou,Michelle T. Marra,Lennert J. Mitchell,Brion W. Murray,James A. Nieman,Stephen Noell,Simon Paul Planken,Thomas Rowe,Kevin Ryan,George J. Smith,James Solowiej,Claire M. Steppan,Barbara Taggart +22 more
TL;DR: Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
Posted ContentDOI
The Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
Robert M. Hoffman,Robert Steven Kania,Jay F. Davies,Rose Ann Ferre,Ketan S. Gajiwala,Mingying He,Robert J. Hogan,Kirk Kozminski,Lilian Y. Li,Jonathan W. Lockner,Jihong Lou,Michelle T. Marra,Mitchell Lennert J,Brion W. Murray,James A. Nieman,Stephen Noell,Simon Paul Planken,Thomas Rowe,Kevin M. Ryan,George J. Smith,James Solowiej,Claire M. Steppan,Barbara Taggart +22 more
TL;DR: Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
Journal ArticleDOI
Solution Formulation Development of a VEGF Inhibitor for Intravitreal Injection
TL;DR: To the authors' knowledge, this is the first time that a nonpolymeric in situ-forming depot formulation has been developed for intravitreal delivery, with the active ingredient as the precipitating agent.
Journal ArticleDOI
2nd Ophthalmic Drug Development and Delivery Summit.
TL;DR: The Second Annual Ophthalmic Drug Development and Delivery Summit was held on 19 – 20 September 2006 in San Diego, CA, US and grew as an efficient platform for fostering discussion on a range of scientific topics and challenges and avenues for building collaborative partnerships in ophthalmic drug development.